Israel Biotech Fund
Venture capitalRehovot · Seed–Series A · 5 people tracked
Also known as I.B.F. MANAGEMENT LTD.
Investment thesis
Israel Biotech Fund invests in biotechnology and pharmaceutical companies based in or connected to Israel, operating across the development and growth stages. The fund focuses on building Israeli biotech enterprises with the objective of delivering capital appreciation to investors.
Source: firm website, verified Aug 11, 2026.
Team · 5 people
from public directories
What they invest in
from 15 of 18 portfolio companiesBiotech ×15Healthtech ×6Medical Devices ×4AI & Machine Learning ×2Deep Tech ×1Digital Health ×1HR Tech ×1Longevity ×1
HQs:United States×6Israel×2
Investments · 18 tracked
founders shown can be your intro pathBy year:2023 · 12017 · 22015 · 36 dated
BiotechHackensack, US
James McGorry(Executive Officer)David Miller(Executive Officer)Daniel Mendelson(Director)Joel Ackerman(Executive Officer, Director)Abba David Poliakoff(Director)Arthur Epker, III(Director)
Board seatDavid Sidransky· per SEC Form D · $14M raise · filed Mar 2015
BiotechTel Aviv
Ran Oren(Director)Tali Gorfine(Executive Officer)Carol Brosgart(Director)Yohai Stenzler(Executive Officer)Liat Hayardeny(Executive Officer)Shmuel Nir(Director)
Board seatDavid Sidransky· per SEC Form D · $350K raise · filed Aug 2017
BiotechYavne
Ety Klinger(Executive Officer, Director)Ofer Gonen(Executive Officer)Boaz Gur-Lavie(Chief Financial Officer)Sharon Malka(Director)Vickie R. Driver(Director)Tzvi Palash(Executive Officer)
AION Labs is a venture studio that creates AI, technology, and science startups focused on pharmaceutical R&D, using a co-development model that gives startups access to pharma expertise, validation opportunities, and pre-seed funding.
AI & Machine LearningBiotechDeep Tech
Vensica is a clinical-stage medical company developing ViXe, a needle-free treatment for overactive bladder that combines the neurotoxin Xeomin with Vibe, an ultrasound-based drug delivery device that microinjects medication into the bladder wall.
BiotechHealthtechMedical Devices
Avner Geva(CEO, Co-founder)Avi Eftel(CTO, Co-founder)Roger R. Dmochowski(CMO)Ken Berlin(Executive Chairman)
BiotechMonmouth Junction, US
Samir Khleif(Director)Richard Berman(Director)Igor Gitelman(Director)Andres Gutierrez(Executive Officer)Roni Appel(Director)Kenneth Berlin(Executive Officer, Director)
Board seatDavid SidranskyYuval Cabilly· per SEC Form D · $433.8K raise · filed Nov 2023
Orgenesis operates the POCare Platform for developing, scaling, and commercializing advanced cell and gene therapies delivered at the point of care.
BiotechHealthtechMedical DevicesGermantown, US
Etti Hanochi(Director)Yaron Adler(Director)Yachin Yachin(Director)Neil Reithinger(Executive Officer)Vered Caplan(Executive Officer, Director)Ferber Ferber(Executive Officer)
Board seatDavid Sidransky· per SEC Form D · $10M raise · filed Dec 2015
BiotechSan Diego, US
Fred Knoll(Director)Patrick Ostronick(Director)John Brancaccio(Director)Jamie Sulley(Executive Officer, Director)Paul Weiss(Director)Joanne Barsa(Executive Officer)
Board seatDavid Sidransky· per SEC Form D · $800K raise · filed Sep 2015
4C Biomed develops immuno-oncology therapies using a patient-derived discovery platform that identifies novel immune targets from autologous cancer and immune cell systems.
BiotechHealthtech
BioSpace is a platform providing news, job listings, and recruitment marketing solutions for the life sciences industry.
BiotechHealthtechHR TechMarketing TechMedia & EntertainmentMedical DevicesSaaSDes Moines, US
Josh Goodwin(CEO)
Ayala Pharma is associated with pharmaceutical drug candidates including AL102, AL101, and BST-236; the page states that AL102 and AL101 were acquired by Immunome, Inc. in Q1 2024.
Biotech
Gamida Cell develops allogeneic cell therapy products using its proprietary nicotinamide (NAM) technology to enhance and expand cells for treating patients with hematologic and non-hematologic conditions.
BiotechHealthtechLongevity
Nectin is a biotech developing a pipeline of targeted immunotherapies, including immuno-oncology antibodies and antibody-drug conjugates (ADCs).
BiotechMedical Devices
SpliSense develops RNA-based therapies using antisense oligonucleotides (ASOs) to restore and modify protein function.
BiotechHealthtech
Ukko develops immuno-therapeutics for life-threatening food allergies using a computational protein design platform.
AI & Machine LearningBiotechDigital HealthMountain View, US
Judith Weiss Paltiel(PhD, VP Development)Anat Binur(Executive Officer, Director)Yanay Ofran(Director)Scott Brady(Director)
BoardSamir Kaul(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioChampions OncologyNASDAQ: CSBRGalmed PharmaceuticalsNASDAQ: GLMDMediwoundNASDAQ: MDWD
Frequently asked questions
- What stage does Israel Biotech Fund invest at?
- Israel Biotech Fund invests at the Seed, Series A stages.
- What sectors does Israel Biotech Fund focus on?
- Israel Biotech Fund focuses on Biotech, Digital Health, Medical Devices.
- Where is Israel Biotech Fund located?
- Israel Biotech Fund is headquartered in Rehovot, IL.
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
Kaiser Permanente Ventures is the corporate venture capital arm investing in healthcare companies that address real needs and deliver value for patients, providers, healthcare delivery systems, and communities.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.